Year Founded
1979
Ownership
Public
Employees
~100
Therapeutic Areas
Men's HealthNeurology
Stage
Commercial
Modalities
Medical devices

Antares Pharma General Information

Antares Pharma, a subsidiary of Halozyme Therapeutics, focuses on commercialized pharmaceutical products and technologies, particularly in male health diseases, migraine, and cluster headache. It employs subcutaneous injection platforms for both generic and branded injectables.

Contact Information

Website
Primary Industry
Pharma
Corporate Office
Ewing, New Jersey
United States of America

Drug Pipeline

Xyosted
Commercial
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Antares Pharma's pipeline data

Book a demo

Key Partnerships

Teva Pharmaceutical Industries Ltd, Ferring Pharmaceuticals, AMAG

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Antares Pharma Funding

Deal TypeDateAmountStatusStage
Later Stage VCJun 7, 2017$35.0MCompletedCommercial
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Antares Pharma's complete valuation and funding history, request access »

Antares Pharma Investors

Halozyme Therapeutics
Investor Type: Venture Capital
Holding: Minority
HSBC
Investor Type: Venture Capital
Holding: Minority
MMV Financial
Investor Type: Venture Capital
Holding: Minority
Investor Name
Investor Type
Holding
Investor Name
Investor Type
Holding
You're viewing 3 of 5 investors. Get the full list »